Immune Checkpoint Inhibitor-Associated Acquired Aplastic Anemia
Katrina Collins
Expert | Attending
Presented at: College of American Pathologists (CAP) Annual Meeting
Date:
Views: 26
Summary: Acquired aplastic anemia, which is thought to result from immune-mediated destruction of hematopoietic stem and progenitor cells, has not been documented pathologically in association with immune checkpoint inhibitor therapy. We present here a case of acquired aplastic anemia, which arose following treatment of recurrent glioblastoma multiforme with the PD-1 inhibitor, nivolumab.